Head to Head Review: Endologix (ELGX) and Its Rivals
Endologix (NASDAQ: ELGX) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it weigh in compared to its rivals? We will compare Endologix to related companies based on the strength of its earnings, valuation, profitability, risk, dividends, institutional ownership and analyst recommendations.
This table compares Endologix and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
54.4% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 3.9% of Endologix shares are owned by insiders. Comparatively, 10.3% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Endologix and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Endologix||$192.93 million||-$154.67 million||-5.41|
|Endologix Competitors||$1.67 billion||$207.58 million||72.64|
Endologix’s rivals have higher revenue and earnings than Endologix. Endologix is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Endologix has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, Endologix’s rivals have a beta of 0.21, meaning that their average stock price is 79% less volatile than the S&P 500.
This is a summary of current ratings for Endologix and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Endologix presently has a consensus target price of $5.36, indicating a potential upside of 6.50%. As a group, “Medical Devices & Implants” companies have a potential upside of 38.86%. Given Endologix’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Endologix has less favorable growth aspects than its rivals.
Endologix rivals beat Endologix on 9 of the 13 factors compared.
Endologix Company Profile
Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with Analyst Ratings Network's FREE daily email newsletter.